

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 November 2018 (08.11.2018)



(10) International Publication Number
WO 2018/204872 A3

(51) International Patent Classification:

A61K 49/14 (2006.01) *A61P 29/00* (2006.01)
A61K 51/08 (2006.01) *A61P 35/00* (2006.01)
A61K 51/10 (2006.01)

(21) International Application Number:

PCT/US2018/031233

(22) International Filing Date:

04 May 2018 (04.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/502,288 05 May 2017 (05.05.2017) US
62/545,945 15 August 2017 (15.08.2017) US

(71) Applicant: FUSION PHARMACEUTICALS INC.

[CA/CA]; 1280 Main Street W, NRB A316, Hamilton, Ontario L8S 4K1 (CA).

(72) Inventor; and

(71) Applicant: BURAK, Eric Steven [US/CA]; 40 James Street, Cambridge, Ontario N1S 1C5 (CA).

(72) Inventors: FORBES, John Richard; 2210 Irving Street, Burlington, Ontario L7L 6T3 (CA). MORAN, Matthew David Burr; 950 Lucerne Crescent, Mississauga, Ontario L5C 3Y6 (CA). SIMMS, Ryan Wayne; 70 Thirteenth Street, Toronto, Ontario M8V 3H6 (CA). VALLIANT, John Fitzmaurice; 15 Holkham Ave., Ancaster, Ontario L9K 1N8 (CA).

(74) Agent: GORDON, Edward, A.; McDermott Will & Emery LLP, 500 North Capitol Street, N.W., Washington, District of Columbia 20001-1531 (US).

(54) Title: IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF




Fig. 1

(57) Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof. The present invention is directed to monoclonal antibodies that target the insulin-like growth factor-1 receptor and the radioimmunoconjugates thereof that demonstrate increased potency and enhance the excretion of a chelating moiety, or a metal complex thereof, when conjugated to a therapeutic moiety, a targeting moiety, or a cross-linking group. In another aspect, the invention features a pharmaceutical composition comprising a compound of the invention; and a pharmaceutically acceptable excipient. In another aspect, the invention features a method of radiation treatment planning and/or radiation treatment, the method comprising administering to a subject in need thereof a compound or pharmaceutical composition of the invention.

[Continued on next page]



WO 2018/204872 A3

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

13 December 2018 (13.12.2018)